When an autoimmune disease disrupted the life of someone close to scientist Dario Gutierrez, an idea emerged for a new company called Merida Biosciences focused on removing misdirected antibodies and their negative effects using Fc biotherapeutics. Read More
Neuroendocrine prostate cancer (NEPC) is the most aggressive form of prostate cancer, responsible for up to 20% of therapy-resistant cases and associated with rapid disease progression. It is characterized by a loss of typical androgen receptor signaling, conferring antiandrogen therapy resistance, and abnormal expression of neuroendocrine markers, along with small cell morphology. Read More
Lyme disease is a multisystemic zoonotic infection caused by Borrelia burgdorferi bacteria transmitted by ticks. Lyme disease is a public health problem because of its high incidence in North America and Europe and its increasing presence due to the impacts of climate change on vector distribution. Novel, effective vaccines to prevent the disease are, therefore, urgently needed. Read More
Orexo AB has announced promising in vivo proof-of-concept data for a powder-based intranasal vaccine candidate based on Abera Bioscience AB’s BERA vaccine platform and formulated with Orexo’s Amorphox technology. Read More
Writing in Molecular Therapy Nucleic Acids, researchers hypothesized that using poly(A) tail mimetics to enhance mRNA expression from haploinsufficiency-associated genes could be a disease-modifying treatment strategy. Read More
Researchers from Voyager Therapeutics Inc. presented preclinical activity data of VY-1706, a blood-brain barrier (BBB)-penetrant gene therapy comprising an adeno-associated virus serotype 9 capsid (AAV9-C9P39) vector encoding primary artificial microRNA (pri-amiRNA) consisting of short-interfering RNA (siRNA) targeting human microtubule-associated protein tau (MAPT) protein. Read More
Several recent Atavistik Bio Inc. patents describe substituted aminopyridine compounds acting as RAC-α serine/threonine-protein kinase (AKT1; PKBα) inhibitors, particularly AKT1 (E17K mutant) reported to be useful for the treatment of cancer. Read More
Metachromatic leukodystrophy (MLD) is an autosomal recessive lysosomal storage disease originating from biallelic pathogenic variants in the ARSA gene, mainly affecting young children. Read More
Aurigene Oncology Ltd. has patented new proteolysis targeting chimera (PROTACs) compounds comprising a protein cereblon (CRBN)-binding moiety covalently bound to a CREB-binding protein (CREBBP; CBP)-targeting moiety through a linker. Read More
Genflow Biosciences plc has announced a development program in ophthalmology focused on advancing a novel gene therapy leveraging its proprietary centenarian SIRT6 (cSIRT6). Read More
Work at Vir Biotechnology Inc. has led to the identification of 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infections (COVID-19). Read More
Nitrated α-synuclein is upregulated in the CSF of patients with Parkinson’s Disease (PD), Lewy body dementia (DLB), multiple system atrophy (MSA), and other synucleinopathies. Read More
Pancreatic ductal adenocarcinom a (PDAC), frequently detected at advanced stages, has a 5-year survival rate of 12%. Metastases are common, including hepatic metastasis, which is particularly lethal due to the liver’s immune-tolerant environment and rich blood supply that facilitate tumor growth. Read More
A Suven Life Sciences Ltd. patent has detailed new N-aryl benzamide derivatives acting as P2X purinoceptor 7 (P2RX7; P2X7) antagonists. As such, they are believed to be potentially useful for the treatment of cancer, pain, renal, neurological, endocrine and psychiatric disorders. Read More
In Parkinson’s disease (PD), damaged mitochondria build up in the dopaminergic system of the substantia nigra, partly due to impaired mitochondrial autophagy (mitophagy) and autophagosome accumulation. Read More
Neddylation is a post-translational modification that conjugates the NEDD8 protein to protein substrates, such as the cullins, which once neddylated join complex to form cullin-RING ubiquitin E3 ligases (CRLs), which in turn play a crucial role in regulating proteasomal degradation. The University of Kentucky has presented preclinical data on their neddylation inhibitor TK-59 as a cancer therapeutic. Read More
Oxford University Innovation Ltd. has reported radiolabeled compounds reported to be useful for the diagnosis and treatment of cancer. An unlabeled form of an exemplified compound ([68Ga]-KK02 pg 33) inhibited PARP1 activity (IC50=9.1 nM). Read More
